CAR-T cell therapy advancements
On April 17, 2026, a phase 1 trial of intraventricular HER2-directed CAR T-cells for HER2-positive breast cancer with CNS metastases demonstrated a manageable safety profile and stable disease rates in heavily pretreated patients. As of April 20, 2026, CAR-T cell therapies are anticipated to grow significantly over the next 5-10 years, with research focusing on refining CAR constructs, improving side effect management, and developing allogeneic platforms. The C406 CAR-T therapy, also targeting HER2-positive breast cancer, showed a 75% disease control rate in a phase I study with manageable adverse events. Additionally, UCLA scientists developed 'armored' CAR-T cells to overcome immunosuppression, showing significant tumor reduction in preclinical models of glioblastoma and ovarian cancer on April 14, 2026. Researchers at the University of Chicago developed GA1CAR, a modular "plug-and-play" CAR-T system, and reported the first successful in vivo engineering of CAR T cells at a therapeutic level for both hematologic and solid cancers on April 13, 2026.
Timeline
Want updates on this thread?
Track this storyTimeline of developments
April 2026 — 10 developments
The development of CAR-T cell therapies for various cancers and autoimmune diseases is anticipated to grow significantly over the next 5-10 years.
The development of CAR-T cell therapies for various cancers and autoimmune diseases is anticipated to grow significantly over the next 5-10 years. Research is focusing on refining CAR constructs for improved specificity and reduced toxicity, developing better management protocols for side effects, exploring allogeneic CAR-T platforms for broader access, and enhancing T-cell trafficking for solid tumors.
A phase 1 trial of intraventricular HER2-directed CAR T-cells for HER2-positive breast cancer with C…
A phase 1 trial of intraventricular HER2-directed CAR T-cells for HER2-positive breast cancer with CNS metastases has shown a manageable safety profile and stable disease rates in heavily pretreated patients. Additionally, a new generation of base-edited CAR T-cells (BE-CAR7) shows promise in treating aggressive T-cell leukemia, contributing to the 'CAR-T 2.0 era' focused on rapid manufacturing and reduced toxicity.
The C406 CAR-T therapy targeting HER2-positive breast cancer demonstrated a 75% disease control rate in a phase I study, with manageable adverse events.
The C406 CAR-T therapy targeting HER2-positive breast cancer demonstrated a 75% disease control rate in a phase I study, with manageable adverse events. Ongoing research continues to focus on developing next-generation CAR-T cells, including GA1CAR, for improved persistence, reduced toxicity, and better tumor microenvironment penetration.
A novel CAR-T therapy targeting HER2-expressing tumors, engineered to secrete a bispecific antibody …
A novel CAR-T therapy targeting HER2-expressing tumors, engineered to secrete a bispecific antibody against HER2 and p95HER2, has demonstrated significant tumor reduction in preclinical models. A Phase 1 clinical trial for this therapy is currently in development.
New research explores next-generation CAR-T cell therapies targeting HER2 for solid tumors, with one…
New research explores next-generation CAR-T cell therapies targeting HER2 for solid tumors, with one novel CAR-T achieving safe, complete, and durable responses in preclinical models, leading to complete tumor disappearance in xenograft models. Concurrently, new CAR-T manufacturing methods are being developed to improve efficacy and reduce costs, including a multi-cytokine scaffold for longer-lived immune cells and a controlled immune response CAR-T for safer blood cancer treatment.
A novel CAR T-cell therapy targeting the HER2 antigen has shown efficacy and safety in preclinical m…
A novel CAR T-cell therapy targeting the HER2 antigen has shown efficacy and safety in preclinical models of HER2-positive solid tumors, including breast and ovarian cancers, and is being explored for integration with radiation therapy. In a Phase I clinical trial for advanced sarcoma, 50% of treated patients experienced clinical benefit, with one patient achieving a durable, cancer-free response lasting over five years.
UCLA scientists have developed 'armored' CAR-T cells engineered to overcome the immunosuppressive tumor microenvironment by blocking VEGF.
UCLA scientists have developed 'armored' CAR-T cells engineered to overcome the immunosuppressive tumor microenvironment by blocking VEGF. These modified cells demonstrated a significant reduction in tumor growth and extended survival in preclinical models of glioblastoma and ovarian cancer.
A universal CAR-T cell immunotherapy has shown promising results in a Phase 1/2 clinical trial for aggressive blood cancers, with most patients achieving full remission.
A universal CAR-T cell immunotherapy has shown promising results in a Phase 1/2 clinical trial for aggressive blood cancers, with most patients achieving full remission. Additionally, an "off-the-shelf" CAR-T therapy demonstrated significant reductions in molecular residual disease (MRD) and achieved MRD clearance in patients with large B-cell lymphoma. Researchers at the University of Chicago developed GA1CAR, a modular "plug-and-play" CAR-T system offering enhanced safety and adaptability.
Researchers have reported the first successful in vivo engineering of CAR T cells at a therapeutic level for both hematologic and solid cancers.
Researchers have reported the first successful in vivo engineering of CAR T cells at a therapeutic level for both hematologic and solid cancers. This advancement, developed by the University of Chicago, aims to make treatments more efficient and precise by engineering T cells within the patient's body. This approach could potentially overcome challenges associated with ex vivo manufacturing.
C406 CAR-T therapy has demonstrated significant potential in preclinical studies for treating various cancers.
C406 CAR-T therapy has demonstrated significant potential in preclinical studies for treating various cancers. This therapy is designed to overcome common challenges in CAR-T treatment, such as tumor resistance and T-cell exhaustion. Further research is ongoing to optimize its efficacy and safety profile for potential clinical translation.
March 2026 — 1 developments
A novel CAR T-cell therapy targeting the HER2 antigen has demonstrated safety and clinical benefit in patients with advanced sarcoma during a Phase 1 clinical trial.
A novel CAR T-cell therapy targeting the HER2 antigen has demonstrated safety and clinical benefit in patients with advanced sarcoma during a Phase 1 clinical trial. Researchers at Baylor College of Medicine and Texas Children's Hospital are leading this study. Another related study reported on a second-generation CAR T-cell therapy targeting p95HER2, which showed safety and complete, durable responses in preclinical models.
January 2026 — 1 developments
New CRISPR-based screening methods are presented, identifying gene targets that could further enhanc…
New CRISPR-based screening methods are presented, identifying gene targets that could further enhance CAR T-cell proliferation and anti-tumor activity, indicating ongoing efforts to refine CAR-T technologies.
December 2025 — 1 developments
A clinical trial for a different CAR-T therapy (GCAR1), an autologous CAR-T for solid tumors, is fir…
A clinical trial for a different CAR-T therapy (GCAR1), an autologous CAR-T for solid tumors, is first posted, with a study start date of January 31, 2026, indicating ongoing clinical translation efforts in CAR-T for solid tumors.
August 2025 — 1 developments
A review article discusses the broader landscape of UCAR-T cell engineering and clinical strategies,…
A review article discusses the broader landscape of UCAR-T cell engineering and clinical strategies, noting progress in hematological malignancies but persistent challenges in solid tumors, underscoring the importance of GA1CAR's advancements.
May 2025 — 1 developments
An international Phase 1/2 clinical trial for a new universal CAR-T cell therapy for aggressive T ce…
An international Phase 1/2 clinical trial for a new universal CAR-T cell therapy for aggressive T cell cancers showed promising outcomes, including high response and remission rates with manageable toxicity.
November 2024 — 1 developments
A universal CAR-T therapy targeting aggressive T-cell cancers has received FDA Breakthrough Status, showing a high overall response rate in a clinical trial.
A universal CAR-T therapy targeting aggressive T-cell cancers has received FDA Breakthrough Status, showing a high overall response rate in a clinical trial. Additionally, a new 'armored' CAR-T cell therapy, enhanced with IL-18, has demonstrated significant responses in lymphoma patients resistant to existing CAR-T treatments.
October 2021 — 1 developments
The concept of Universal CAR-T (UCAR-T) cell therapy gains significant attention as a strategy to overcome the manufacturing and cost limitations of autologous CAR-T.
The concept of Universal CAR-T (UCAR-T) cell therapy gains significant attention as a strategy to overcome the manufacturing and cost limitations of autologous CAR-T.
August 2017 — 1 developments
The U.S. FDA grants approval to Kymriah (tisagenlecleucel), the first CAR T-cell therapy, for acute …
The U.S. FDA grants approval to Kymriah (tisagenlecleucel), the first CAR T-cell therapy, for acute lymphoblastic leukemia (ALL), marking a major regulatory and clinical breakthrough.
January 2010 — 1 developments
The first successful clinical application of CAR T-cells in a patient with chronic lymphocytic leuke…
The first successful clinical application of CAR T-cells in a patient with chronic lymphocytic leukemia (CLL) at the University of Pennsylvania achieves complete remission, demonstrating the therapy's potential.
January 2003 — 1 developments
Dr. Michel Sadelain's group introduces CD19-targeting CAR T cells, a pivotal development that sets t…
Dr. Michel Sadelain's group introduces CD19-targeting CAR T cells, a pivotal development that sets the stage for effective CAR T-cell therapies in hematological malignancies.
January 1993 — 1 developments
Landmark studies demonstrate the ability to genetically engineer human T cells to recognize and kill…
Landmark studies demonstrate the ability to genetically engineer human T cells to recognize and kill cancer, and the first-generation CARs are created, though initial in vivo efficacy is limited.
January 1987 — 1 developments
The foundational concept of chimeric antigen receptors (CARs) is first proposed by researchers, laying the theoretical groundwork for CAR T-cell therapy.
The foundational concept of chimeric antigen receptors (CARs) is first proposed by researchers, laying the theoretical groundwork for CAR T-cell therapy.